Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a 25% revenue increase and improved net loss and gross margin, the lack of strategic and operational updates, alongside increased operating expenses, balances the sentiment. The absence of shareholder return discussions and vague management responses in the Q&A add uncertainty. Overall, these mixed signals suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue Biofrontera Inc. reported revenue of $10 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to higher sales volume driven by increased demand for the company's dermatology products.
Net Loss The company reported a net loss of $2 million for Q1 2026, which is an improvement from the $3 million net loss in Q1 2025. The reduction in net loss was due to cost optimization measures and improved operational efficiency.
Gross Margin Gross margin improved to 65% in Q1 2026, up from 60% in Q1 2025. The improvement was driven by better pricing strategies and reduced production costs.
Operating Expenses Operating expenses were $5 million in Q1 2026, a 10% increase compared to Q1 2025. The increase was primarily due to higher marketing and R&D expenditures.
Cash Flow Cash flow from operations was negative $1 million in Q1 2026, compared to negative $2 million in Q1 2025. The improvement was attributed to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that actual results may differ materially from forward-looking statements due to risks and uncertainties associated with its business.
Time-sensitive information: The company highlights that the information shared is accurate only as of the date of the live broadcast, indicating potential risks of outdated or irrelevant data if not updated.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aschoff ROTH
Bruce Jackson
CEO President
Capital Partners
Chairman George
Chief Commercial
Chief Financial
Commercial Officer
Division Bruce
Division day
EDT Jonathan
Eugene Leffler
Financial Officer
George Jones
Hermann Lubbert
Inc Financial
Investor Relations
Jackson Benchmark
Jonathan Aschoff
Jones Chief
LLC Research
Leffler Chief
Lubbert CEO
Officer EDT
Officer Eugene
Partners LLC
President Chairman
ROTH Capital
Relations today
Research Division
conference Investor
day Inc
BFRI Transcript
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Unknown5-14
Despite a 25% revenue increase and improved net loss and gross margin, the lack of strategic and operational updates, alongside increased operating expenses, balances the sentiment. The absence of shareholder return discussions and vague management responses in the Q&A add uncertainty. Overall, these mixed signals suggest a neutral stock price movement in the short term.
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Positive3-19
Biofrontera's earnings call highlights strong revenue growth, record high quarterly revenue, and significant improvements in gross profit margins and net income. The company's strategic initiatives, including product expansion and cost management, are on track, with optimistic guidance for 2026. Despite risks like legal costs and competition, the overall sentiment is positive, supported by improved financial metrics and promising product developments. The lack of concerning responses in the Q&A further solidifies the positive outlook for the stock price over the next two weeks.
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call highlights increased net loss, decreased revenue, and high legal expenses, which are negative indicators. The Q&A suggests potential for future growth with planned price increases and FDA submissions, but these are not immediate catalysts. Limited cash reserves pose liquidity risks, and ongoing legal costs are concerning. Overall, the financial health and immediate outlook are weak, leading to a negative sentiment.
Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript
Positive8-14
The earnings call highlights a strong financial performance with a 15.4% revenue increase and reduced cost of revenues. Despite a net loss, the significant reduction in costs and improved adjusted EBITDA are promising. The Q&A section reveals positive sentiment towards gross margin improvements and upcoming FDA submissions. Although legal costs increased, they are not expected to persist. The lack of a price hike and expected cash inflow further support a positive outlook. Overall, the financial and strategic updates suggest a positive stock price movement in the next two weeks.
BFRI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
